116 related articles for article (PubMed ID: 21412089)
1. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience.
Petralia G; Fazio N; Bonello L; D'Andrea G; Radice D; Bellomi M
J Comput Assist Tomogr; 2011; 35(2):195-201. PubMed ID: 21412089
[TBL] [Abstract][Full Text] [Related]
2. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
3. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Sacco R; Faggioni L; Bargellini I; Ginanni B; Battaglia V; Romano A; Bertini M; Bresci G; Bartolozzi C
Dig Liver Dis; 2013 Sep; 45(9):776-81. PubMed ID: 23578581
[TBL] [Abstract][Full Text] [Related]
4. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.
Hayano K; Lee SH; Yoshida H; Zhu AX; Sahani DV
Acad Radiol; 2014 May; 21(5):654-60. PubMed ID: 24703479
[TBL] [Abstract][Full Text] [Related]
5. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
6. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
[TBL] [Abstract][Full Text] [Related]
10. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.
Sahani DV; Holalkere NS; Mueller PR; Zhu AX
Radiology; 2007 Jun; 243(3):736-43. PubMed ID: 17517931
[TBL] [Abstract][Full Text] [Related]
11. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
Faria SC; Ng CS; Hess KR; Phongkitkarun S; Szejnfeld J; Daliani D; Charnsangavej C
AJR Am J Roentgenol; 2007 Aug; 189(2):378-85. PubMed ID: 17646464
[TBL] [Abstract][Full Text] [Related]
12. Quantification of variability in breath-hold perfusion CT of hepatocellular carcinoma: a step toward clinical use.
Petralia G; Summers P; Viotti S; Montefrancesco R; Raimondi S; Bellomi M
Radiology; 2012 Nov; 265(2):448-56. PubMed ID: 22996748
[TBL] [Abstract][Full Text] [Related]
13. Liver perfusion CT during hepatic arteriography for the hepatocellular carcinoma: dose reduction and quantitative evaluation for normal- and ultralow-dose protocol.
Watanabe S; Katada Y; Gohkyu M; Nakajima M; Kawabata H; Nozaki M
Eur J Radiol; 2012 Dec; 81(12):3993-7. PubMed ID: 22980216
[TBL] [Abstract][Full Text] [Related]
14. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.
Liang PC; Ch'ang HJ; Hsu C; Chen LT; Shih TT; Liu TW
Hepatol Int; 2015 Apr; 9(2):258-68. PubMed ID: 25788178
[TBL] [Abstract][Full Text] [Related]
15. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
16. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
Bertolotto M; Pozzato G; Crocè LS; Nascimben F; Gasparini C; Cova MA; Tiribelli C
Invest Radiol; 2006 Jan; 41(1):15-21. PubMed ID: 16355035
[TBL] [Abstract][Full Text] [Related]
17. Perfusion computed tomographic assessment of early hepatocellular carcinoma in cirrhotic liver disease: initial observations.
Ippolito D; Sironi S; Pozzi M; Antolini L; Ratti L; Meloni F; Invernizzi F; Valsecchi MG; Fazio F
J Comput Assist Tomogr; 2008; 32(6):855-8. PubMed ID: 19204443
[TBL] [Abstract][Full Text] [Related]
18. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
[TBL] [Abstract][Full Text] [Related]
19. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization.
Ippolito D; Sironi S; Pozzi M; Antolini L; Invernizzi F; Ratti L; Leone EB; Fazio F
Eur J Radiol; 2010 Jan; 73(1):148-52. PubMed ID: 19054640
[TBL] [Abstract][Full Text] [Related]
20. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
